Skip to content
akaturk Academic measurement

OpenAlex topic

Multiple Sclerosis Research Studies

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 4,820 works 222 author topics

Works

4,820 works

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. METHODS: Of a total of 942 patients, 627 were randomly assigned to receive natalizuma…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 stu…

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 stu…

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dos…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS: We randomly a…

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS: We randomly a…

  8. OpenAlex top 1% OpenAlex 99.6%

    OBJECTIVE: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC). Given the side effects of this regimen, we evaluated the efficacy and the toxicity of a course of low-dose IV CYC prescribed as a rem…

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS: We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the…

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  11. OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

Academicians

222 academicians